Europe was LivaNova’s largest region in fiscal 2025, bringing in $470.22M of $1.05B (45%).
| Geography | FY 2014 | FY 2015 | FY 2015 | FY 2016 | FY 2017 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| U.S. Pension Benefits | $374.54M | $407.49M | $441.02M | $463.60M | ||||||
| U.S | — | — | — | — | ||||||
| United States | — | — | — | — | ||||||
| Europe | $307.35M | $157.41M | $388.06M | $470.22M | ||||||
| Rest Of World | $52.16M | $244.34M | $273.03M | $64.19M | ||||||
| Uk Nol | $32.30M | $41.50M | $48.90M | $55.90M | ||||||
| United Kingdom | — | — | — | — | ||||||
| Total | $766.35M | $850.75M | $1.15B | $1.05B |
LivaNova brought in $1.05B from its four regions in fiscal 2025, the year ended December 31, 2025. That was down 8.4% from $1.15B in fiscal 2024. Europe was the largest at $470.22M (44.6%), ahead of U.S. Pension Benefits at $463.60M (44.0%) and Rest Of World at $64.19M (6.1%). The remaining region, Uk Nol, brought in $55.90M.
Compared with fiscal 2024, Europe grew fastest, up 21.2% to $470.22M, while Rest Of World fell the most, down 76.5% to $64.19M. From fiscal 2022 to 2025, combined revenue from these regions grew from $766.35M to $1.05B, a compound annual growth rate of 11.2%. Europe's share of the total rose from 40.1% to 44.6%.
Neuromodulation was LivaNova’s largest segment in fiscal 2025, bringing in $463.60M of $772.08M (60%).
| Segment | FY 2014 | FY 2015 | FY 2015 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiopulmonary | $514.20M | $604.11M | $273.03M | $308.48M | ||||||||
| Neuromodulation | $52.16M | $57.44M | $441.02M | $463.60M | ||||||||
| Cardiovascular | — | — | — | — | ||||||||
| Cardiac Surgery | — | — | — | — | ||||||||
| Advanced Circulatory Support | — | — | — | — | ||||||||
| Total | $566.36M | $661.55M | $714.05M | $772.08M |
LivaNova brought in $772.08M from its two segments in fiscal 2025, the year ended December 31, 2025. That is less than the $1.05B it reports by geography, so these segments do not cover all of its revenue. Neuromodulation was the largest at $463.60M (60.0%), ahead of Cardiopulmonary at $308.48M (40.0%).
Compared with fiscal 2024, Cardiopulmonary grew 13.0% to $308.48M and Neuromodulation grew 5.1% to $463.60M.
Cardiopulmonary was LivaNova’s largest product and service line in fiscal 2018, bringing in $536.41M of $681.83M (79%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 |
|---|---|---|---|
| Cardiopulmonary | $474.44M | $650.15M | $536.41M |
| Heart Valves | $137.28M | $209.29M | $125.96M |
| Advanced Circulatory Support | — | — | $19.46M |
| Total | $611.72M | $859.44M | $681.83M |
LivaNova brought in $681.83M from its three product and service lines in fiscal 2018, the year ended December 31, 2018. LivaNova regrouped these lines after fiscal 2017, so the total does not compare directly with that year's $859.44M. Cardiopulmonary was the largest at $536.41M (78.7%), ahead of Heart Valves at $125.96M (18.5%) and Advanced Circulatory Support at $19.46M (2.9%).
Compared with fiscal 2017, Cardiopulmonary fell 17.5% to $536.41M and Heart Valves fell 39.8% to $125.96M.
LivaNova began breaking out Advanced Circulatory Support in fiscal 2018, when it brought in $19.46M.
LivaNova (LIVN) reports its revenue by geography, by segment and by product and service. In fiscal 2025, Europe was its largest region, bringing in $470.22M (44.6% of the total), followed by U.S. Pension Benefits at $463.60M (44.0%).
Europe was LivaNova's largest region in fiscal 2025, bringing in $470.22M, or 44.6% of the $1.05B total across its four regions.
Neuromodulation was LivaNova's largest segment in fiscal 2025, bringing in $463.60M, or 60.0% of the $772.08M total across its two segments.
Cardiopulmonary was LivaNova's largest product and service line in fiscal 2018, bringing in $536.41M, or 78.7% of the $681.83M total across its three product and service lines.
Among LivaNova's regions that make up at least 2% of revenue, Europe grew fastest in fiscal 2025, up 21.2% from $388.06M to $470.22M.
Every figure comes from LivaNova's annual financial filings, as reported. Each line keeps the name LivaNova gives it, and years follow its fiscal calendar.
LivaNova's revenue by geography goes back to fiscal 2014, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.